Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It is interesting to see why someone has acquired 700,000 shares today.
Burger is attempting to get omeone interested in the technology but IMO, it is worthless.
Someone is interested in the shell and that may be who is buying. There are only about 2.5 million shares outstanding so whoever bought today has almost a third of the shares. If they get control, they could take the company into chapter, get rid of the debt, put new money into the company, change the name and press on with whatever they want to do. They must act quickly because the more stale the SEC filings become, the more difficult it becomes.
Is this accurate?
Currently à 4,508,746,417
Please contact me directly with any questions.
Thank you!
Chalan Harper
Executive Assistant/Client Services
BB I will tell you that RXPC is in no way a long term investment. What you or anyone else do short term, that is up to you. My comments on these boards are directed toward anyone who might be thinking RXPC will survive or that Onko Sure will gain enough sales to be a viable product. It just wont happen. Absolutely no one is going to buy Radient, merge with Radient or invest in Radient.
All of the stuff on the board about Provista, GCDX and such is just garbage.
Top penny, you say it must be worth something because they spent money on a patent application. I do agree that MacLellan has not given up totally because he is still attempting to sell Onko Sure. So, since he has not given up, he had to pay for the patent application or there is nothing left. One patent has already expired, the second expires in a year so after next year, without paying for the patent application, there would be nothing left at all.
As for the combination of Onko Sure with other markers, the studies you refer to are by Radient. Do you see a problem there? ....by Radient....no one else says the combinations work. When those press releases were made, the data was NEVER published....big problem.
There was one study published by an independent source in England using Onko Sure combined with two other markers and the conclusion was that it could NOT be used to screen for colorectal cancer. So you have Radient, who is attempting a last ditch survival claiming combinations work and an independent study using two additional says it does not work. Who would you believe?
Would you believe a company who stated claims that the Mayo clinic was running studies for them? Would you believe a company who claimed the Mayo clinic was testing a new version of Onko Sure for them? Would you believe a company who claimed there was a government program in India to use Onko Sure?
The fact is that Maclellan lies.
Top Penny, in order for Radient to survive, two things have to happen. First, there has to be some viable business plan. Onko Sure is the only product they have and it is unlikely to ever sell good enough to make money.
Second, the debt has to be resolved and it continues to grow with huge penalties and interest. That debt has to go away in order for Radient to get more financing. If for some unlikely reason Onko Sure became a viable product, Radient would have to go chapter in an attempt to resolve the debt but there is a HUGE obstacle to that. The lenders have a provision where their debt carries through bankruptcy so their debt cannot be cleared and it is impossible for Radient to obtain any more financing.
This company is just dead. Their product is 40 year old technology and not in demand.
Radient cannot operate out of a garage and sell test kits. Manufacturing facilities need to be approved.
The monthly lease payments are $7,000 and as of the last filing by Radient, they were non current in lease payments. A lot of posts have false information. There is no combination test with Onko Sure with GCDX or anyone else.
That would be something that would have pumped the stock and MacLellan certainly would have made it public if it were true.
There is just no information at all for this stock. Even the TA is no longer telling anyone how many shares are outstanding.
The one thing that is certain, shares continue to be made available at .0001.
Top Penny, I wish you luck but I doubt anything will happen. As for the production increase mentioned by MacLellan, It has been about 18 months since any hard numbers were mentioned so you never know how low the numbers have dropped for him to say there was an increase. We just don't know anything about production but it is not significant enough to warrant any news from Radient or we would have seen it. Also, MacLellan is a known liar.
Thank you Top Penny, I have been maintaining the IBOX as up to date as I can. Even though that email was not official, I accepted it for what it was.
LC Sentinel is NOT a combination test.
Look at the press release made in 2010.
"Gartner said the new diagnostic tool will be ready for the market based on successful study results.
Provista teamed with Tustin, Calif.-based Radient Pharmaceuticals Corp. on the study, which tested 110 blood samples of men and women ages 20 to 76. The tests had a 97 percent accuracy rate based on industry standards, Gartner said.
Now, the companies are jointly developing the lung cancer test for widespread use. Radient will manufacture the test, and it will be sold through Provista’s distribution channels of physicians, medical clinics and hospitals.
Later next year, Gartner plans to register the product with the U.S. Food and Drug Administration."
Several things stand out in that press release.
1. It is just an Onko Sure test directed toward Lung Cancer.
2. Stated that LC Sentinel would be ready for market based on successful study results. What happened? Poor study results?
I called Provista and spoke directly with the lab director in 2011. He stated that additional studies were being run and he expected it to be on the market before the end of quarter 2, 2011. Didn't happen.
The director also confirmed that it was an Onko Sure test directed toward lung cancer. Instead of the general studies Radient has made, extensive specific studies with smokers was needed.
So definitely NOT a combination test with anything else.
I made a post regarding this conversation in early 2011. Anyone with a premium membership can search and find it.
7. Overall reexamination pendency
a. Average pendency 25.4 (mos.)
b. Median pendency 19.6 (mos.)
Jimtash, the above is from the Jan 2012 data from the patent office.
Notice that the average reexamination waiting period is over 2 years. Where did you get the idea that the reexamination process would be faster?
Also take note of the following additonal data on claims.
– PATENT OWNER REQUESTER …………………………………..3148
(1) All claims confirmed 666 21%
(2) All claims canceled 279 9%
(3) Claim changes 2203 70%
So of all the reexaminations, the odds of all claims being confirmed is only 21 per cent. You should read the comments by the examiner. There were additional objections in addition to the prior art from GenWay which was the only one addressed in the resubmission.
Your wishful thinking that a patent issue would be a pump for the stock is a HUGE long shot and any news is likely to be years away instead of a few months as you are stating.
Jimtash, you have a total lack of DD. LC Sentinel was just an Onko Sure test. Can an Onko Sure test be used to monitor lung cancer? IMO, yes it can but can it be FDA approved? It would be near impossible. Can GCDX sell an unapproved test? Sure. that would come under the home brew rules but they cannot distribute the test. That would be illegal.
There are a lot of universal cancer markers that have been discovered.
DR-70, RECAF, HaaH have made their attempt at marketing but others have never been developed.
RECAF was a Texas corp operating out of Canada and they just recently had a lender foreclose and take all the assets. The stock still trades under BOCX.
HaaH was a marker that Panacea Pharmaceuticals attempte to market as a home brew test. They took the same test and called it different names. LC Detect, OV Detect, PC Detect and there may have been others but it was just the same test in a different package. It was a private corp out of Maryland that could no longer get any financing. All the employees left and some sued the company for past wages. Now, I see that the CEO of the corp has done a reverse merger with a Nevada registered defunct oil lease company and has now also based their "new" company out of Canada. The new company trades under PANG.
http://www.panaceaglobalinc.com/breakthrough-cancer-detection-test-could-soon-be-available-in-canada/
That company is a scam also because their test will never develop any following from the medical community.
Dcspka, LC Sentinel is not a combined test at all. It is just a DR-70/ Onko Sure test, nothing more.
Remember, Onko Sure is a test that will show positive for fibrin degradation. For a long time, Radient attempted to obtain FDA approval to detect cancer but was not successful. Once they decided to seek clearance for the use of fibrin degradaton products to monitor colorectal cancer, they got it approved for that use.
Just as the test monitors CRC, Provista wanted to used DR-70/Onko Sure to monitor Lung cancer. Now, I totally agree that it could be used to monitor lung cancer or any other cancer but the problem would be FDA approval. There is no precedent for the test like there was for colon cancer so it would have required full blown expensive clinical trials which probably would not be approved anyway. That is why Provista continued to drag their feet on LC Sentinel and finally dropped it.
Now once and for all, get it out of your head that LC Sentinel was some sort of combination test. It was just an Onko Sure test, nothing more.
Jimtash, that study in no combination of anything. That is just DR-70 used to monitor HCC just like it was cleared by the FDA to monitor CRC.
You guys crack me up with your created fallacies.
Dcspka, You need to do a tiny bit of DD. LC Sentinel was just an Onko Sure test, nothing more. There is no combination of anything. A couple years ago I called Provista and asked about LC Sentinel and that is just what it was.
"Gartner said the new diagnostic tool will be ready for the market based on successful study results.
Provista teamed with Tustin, Calif.-based Radient Pharmaceuticals Corp. on the study, which tested 110 blood samples of men and women ages 20 to 76. The tests had a 97 percent accuracy rate based on industry standards, Gartner said.
Now, the companies are jointly developing the lung cancer test for widespread use. Radient will manufacture the test, and it will be sold through Provista’s distribution channels of physicians, medical clinics and hospitals.
Later next year, Gartner plans to register the product with the U.S. Food and Drug Administration."
The above is from a 2010 article.
http://www.bizjournals.com/phoenix/print-edition/2010/11/12/provista-developing-early-test.html?page=all
Dcspka, you posted a website citing a study done with DR-70 for Liver cancer.
Here are the facts about that study which in fact proves everything I have been stating about Onko Sure for the past several years. It is not an effective test for cancer and that is why the marketing for Onko Sure failed and Radient closed their doors.
Below is the quote from the study.
"DR-70 provided a sensitivity of 81.6% and a specificity of 77.1% for HCC."
The conclusion for the study states that DR-70 is equal to the performance of an AFP test. (AFP is a seldom used test and should only be used to assist in determining if a "mass" found via a CT or MRI is cancer).
If you look up the use of AFP for cancer, it states that it should only be used to monitoring HCC or in those cases where HCC is suspected (mass found). AFP is not a widely used test and it is mostly used in the Orient as is also where DR-70 is also mostly used.
You should look at the performance numbers for the test.
81.6 sensitivity. That means it misses 18.4% of the actual cancers that exist but it also has a whopping 22.9% of fales positives when given to people who have no cancer at all.
If you give the test to 10,000 healthy people, it would indicate that 2290 of that 10,000 have cancer when they no cancer at all.
Now look at the rate of HCC in 10,000 people with actual seer statistics. The below data comes from the National Cancer Institute.
"Asian/Pacific Islander
2.14 per 10,000 men
.82 per 10,000 women"
Given the above data, if you screen 10,000 Asian men, you might be able to find just less than 2 actual cases but you would have 2,290 false positives.
For Asian women, you would possibly find only one cancer and 2,290 false positives.
The numbers just DON'T lie. That is a horrible test for screening and also not an effective test to even determine if a "mass" is actually a cancer.
You can state whatever you want but the facts are facts and that is why Radient has failed. You just need to face reality. You just cannot change the facts. No additional patent is going to cure the problem with the test. The test is what it is and just not very good. DR-70 is called DR-70 because it was first discovered in the 1970's and is now almost 40 year old technology and still no market for the test.
Dcspka, the study you cited just clearly proves what I have been consistently stating for the past few years. DR-70/Onko Sure is not an effective test for any type of cancer.
That is clearly the reason why Radient has failed to be a viable company.
Dcspka, the numbers don't lie. The data is from the national cancer stastics and that is why Onko Sure is such a non reliable test. So is AFP, they both have horrible numbers of false positives.
If you want to read how AFP might be used, look at the site below. It should be used only when a liver mass is detected via other means, most usually CT scans or MRI's. It is NOT for any kind of screening nor is it even accurate when a mass has been found.
http://www.cancer.org/cancer/livercancer/detailedguide/liver-cancer-diagnosis
Dcspka, below is the quote from the study.
"DR-70 provided a sensitivity of 81.6% and a specificity of 77.1% for HCC."
The conclusion for the study states that DR-70 is equal to the performance of an AFP test.
If you look up the use of AFP for cancer, it states that it should only be used to monitoring HCC or to screen those cases where HCC is suspected. AFP is not a widely used test and it is mostly used in the Oreint as is also where DR-70 is mostly used.
You should look at the performance numbers for the test.
81.6 sensitivity. That means it misses 18.4% of the actual cancers that exist but it also has a whopping 22.9% of fales positives when given to people who have no cancer at all.
If you give the test to 1000 healthy people, it would state that 2290 of that 10,000 have cancer when they don't.
Now look at the actual rate of HCC in 10,000 people screened for actual seer statistics.
"Asian/Pacific Islander
2.14 per 10,000 men
.82 per 10,000 women"
Given the above data, if you screen 10,000 Asian men, you might be able to find just less than 2 actual cases but you would have 2,290 false positives.
That is a horrible test for screening
What a joke. Does anyone think someone is really going to read an article that is 10 years old and make comments wanting the test?
Someone on the yahoo board faked the comment and response.
There will be NO tier change and Radient does not have the money to continue SEC filings. in 2012, Radient was loaned money by the lenders to bring the filings up to date in order for the lenders to be legal in selling shares. Two filings were required but Radient only filied the 10K for 2011 and failed to even file the 10Q for quarter one 2012.
The 10k was the last filing Radient made and the lenders probably did not even get the money back via stock sales. Sales by the lenders have not even kept up with the accuring interest on the loans. More money is owed today that was owed in 2012.
That is the total fallacy in the "creeping" takeover hyped on the yahoo board. No company is going to attempt a takeover by purchasing stock when they still end up owing more the longer they wait. All any company would need to do is become a debtor of possession, have Radient file for chapter 11, void all the shares, issue new stock to the debtor in possession and pay off the debt. All the current shareholders would have plenty of shares to paper their bathroooms and the debtor in possession would have total ownership of Radient.
Now, once they have possession, what would they have for the $18 plus million they spent? A product with expired patents that last sold less than $300,000 in sales. Even at current prime of 3.25%, the $18 million they spend would cost $600,000 per year.
Anyone thinking this company has value obviously has no financial savvy at all.
The two 10 million trades were not "buys". They were sales hitting the bid at .0001.
The lack of posting is directly related to the lack of demand for the stock.
Today there are 57 million on the bid at .0001 and 218 million for sale at the ask. A ton more want OUT than want in. A few weeks ago during the SRL hype, there was a lot more buyers.
What most did not realize about the SRL hype is that SRL is not a distributor of Radient. Umesh Bhatia of the failed Gaur Diagno gave the kits he had remaining to SRL in an attempt to get some of his money back. The kits were probably about to expire so SRL was hyping the product in an attempt to sell them before expiration.
That's the real story about SRL.
It definitely looks like the gamblers who were supporting this stock have finally faced the reality that Radient is not worth the gamble to buy any more shares.
Looks like the end of the line may be near for Radient. All that is left is for the remaining shares to be dumped by the lenders calling it a day.
Looks like the lenders are waiting to see if anyone will still buy at .0002. If no one bites, the lenders will indeed begin hitting the ones again. At that point, it will be too late for anyone to escape this stock even at .0001.
The last small bump was from the advertisement by SRL attempting to sell their remaining stock of DR-70 tests. SRL is not a distributor of Radient but a distributor of Gaur Diagno. At one point in 2011, Umesh Bhatia was forced to buy 100 test kits from Radient when they were hyping a fake Indian Government program. Umesh was stuck with the kits so he made a deal with SRL in an attempt to unload the test kits.
I doubt you will hear any more from SRL because Indian doctors are savvy enough to understand that Onko Sure is not an accurate screen for cancer. Without any more pumping type news, the gamblers buying this stock are sure to lose.
Someone on the Yahoo board is now reporting an email from the TA with the outstanding share count at 4 billion. In the past month, the count has gone from 3.6 billion to 4 billion so it is proof the lenders are indeed selling shares.
Dcspka, I will take your post and correct the misleading information.
More news from the blogger underdawg. I sent him an e-mail, this was his reply (this news is currently being blocked by Yahoo hackers):
Yahoo does not allow any links to be posted so if you attempt to post a link, the entire post will be removed.
"Still believe there are operations going on behind the scenes at Radient Pharmaceuticals. The only update we have since October is that Radient has requested the USPTO to reconsider their new patent for Onko-Sure, and the USPTO has initiated the re-evaluation process. This was requested 1 day before the deadline of the patent application being completely terminated.
Even though the patent office publishes a date for a response, there is a 6 month grace period so the application was not going to "go away" as stated above.
That's the new patent which will be effective for all types of cancer, so really whomever gets FDA approval to manufacture kits, Radient owns the patent for this type of technology.
The previous two patents were also for all types of cancers so there is nothing new there. Also, specific cancers are NOT mentioned and there is very little different between the new application other than the mention of monitoring. Combinations with other markers are NOT MENTIONED.
You can get a glimpse of how this works with the latest Global Cancer DX licensing for Lung Cancer. Who knows whats going on now, but this company is owned by Provista Diagnostics and you can get an idea of who wants to have full control of the cancer diagnostics in the United States. And it's Radient Pharmaceuticals who has the determining factor on who gets a license for each and every type of cancer test in the US. In other countries like India, they are using Onko-Sure for all types of cancer.
The first patent has already expired and the second patent is due to expire in 13 months. An expired patent allows another company to use the stated technology without paying any royalties so for just cancer testing, the expiration of the first patent is all another company needs to begin selling the test.
I still don't know exactly how this will play out. With all the manipulation involved, who knows, but I don't think Radient will go bankrupt. They have operations and just not reporting anything, and most likely the share price will go back up on a probable upcoming favorable press release."
For Radient to be successful, they would need a product that has substantial value. Onko Sure has proven to not sell well enough to even pay for its production. If Radient was able to somehow get someone interested in financing, the company loaning the money would certainly want the current shares to be voided to not dilute their infusiong of cash.
There is no way that current investors are going to get anything out of Radient stock.
One thing is clear, after the last major dumping, not so many are willing to gamble even at .0001 any longer.
I went back and looked at the daily trades for the massive dumping at .0001 and those sales were not reported as unresolved trades. They were apparently trades from someone who actually held the stock and finally gave up.
I did report the lenders to the SEC for selling unregistered shares so maybe that is why the volume dried up. For them to be selling is certainly not legal in a non SEC current stock.
Jimtash, there is NO WAY to put any positive slant on the dumping of shares on Friday. If you did not notice, those sales were all at $.0001 and the 500 million on the ask at .0001 you had been praising so much for the past few weeks got eaten severely leaving about 50 million remaining on the ask.
It is also obvious that some of that 500 million was quickly deleted when the massive dump began.
Again, there can be no positive slant on the dumping that occurred. It is just a fact so face it.
Heavyweight, this was what was in the press release.
Radient said it was making "progress on its clinical study with Mayo Clinic for the validation of the company's US FDA-cleared Onko-Sure" ...
That is what got MacLellan in hot water and why the Mayo Clinic denied they were conducting clinical studies using Onko Sure. The Mayo clinic was not conducting any studies whatsoever with onko sure.
Jimtash, the lack of participants on this board is directly related to the lack of desire to own the stock and the fact that Radient has not filed any information about the company in the past 7 months. If there was anything positive, Maclellan would certainly file an 8K.
What MacLellan is worried about now is pleasing the lenders. He is still open for personal liablity in making false statements to the lenders in order to obtain the previous loans.
Radient can not do a reverse split. The previous authorization has expired. They cannot afford to have another shareholder meeting and FINRA would not approve one without the SEC filings being current.
That sure put a dent in the ask at $.0001.
I agree that 300 million has to be lender selling. I also believe they are not even bothering to convert. It is a fact also that they cannot legally sell shares when Radient is not current with SEC filings so if they are illegally selling anyway, why not just illegally sell short with a cooperating off shore broker.
Jimtash, why do you think Onko Sure suddenly has value when the facts prove it is a losing product.
Vulcan, the stock was at $2 because MacLellan was lying in press releases. That is why he is being sued. The stock has no value then just like it has no value now.
Mac said CIT was going into clinical trials. IT WAS A LIE.
Mac said the Mayo Clinic was runing trials for a new version of Onko Sure. IT WAS A LIE.
Mac said there was a government program in India to sell onko Sure. IT WAS A LIE.
Jimtash, below is a typical patent application up for re-examination.
Notice that the date was 6/13/ 2011 so that is 22 months and still waiting. THERE IS A HUGE BACKLOG.
This stock will probably not even be around in 2 to 3 years so hyping a patent application does little.
Bibliographic Data
Application Number:
11/811,590
Customer Number:
-
Filing or 371 (c) Date:
06-11-2007
Status:
Docketed New Case - Ready for Examination
Application Type:
Utility
Status Date:
06-13-2011
Examiner Name:
NATARAJAN, MEERA
Location:
ELECTRONIC
Group Art Unit:
1643
Location Date:
-
Confirmation Number:
6896
Earliest Publication No:
US 2007-0237760 A1
Attorney Docket Number:
MORO-1 CONT IV
Earliest Publication Date:
10-11-2007
Class / Subclass:
435/007.230
Patent Number:
-
First Named Inventor:
Ricardo J. Moro , West Vanvouver, (CA)
Issue Date of Patent:
-
Entity Status:
Undiscounted
AIA (First Inventor to File):
No
Jimtash, the real question here is why anyone would think this stock has any value when DR-70/Onko Sure has been around for years, failed in a launch attempt in 2001 and failed to gain any significant market after a second attempt at a launch in 2009.
The reason it failed in 2001 was the high rate of false positives. Nothing has changed with the product so the false positive rate is still high. GenWay has dropped the product so where is the supposed value in this stock? Just because you can buy millions of shares for pennies does not mean the stock is a good investment.
First it was Provista going to buy Radient.
Next it was Agensys going to buy Radient but OOPS, Reyno resigned.
Then it was GCDX going to merge with Radient.
Then it was the Chinese company ripping off DR-70 was claimed to be a new licensee of Radient.
That certainly wasn't true so then it was waiting for a patent to be approved. There is a huge backlog for patent application re-examinations but that doesn't stop the hype of "soon to be approved" even though the patent has other issues to be resolved. I know of another patent application that has been waiting for re-examination for almost two years.
The fact remains that Radient has not filed ANY financial reports to the SEC for all of 2012 and 2013 and someone keeps selling a huge number of shares.
The most foolish comment I've seen is that the stock must be good because some posters do not like it.